Cargando…
Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)
SIMPLE SUMMARY: Cardiovascular disease is common in patients with small cell lung cancer, partly reflecting its high correlation with smoking. Cardiovascular comorbidities may limit patient tolerance to cytotoxic drugs, thereby influencing the choice and intensity of treatment and, ultimately, patie...
Autores principales: | Gezelius, Emelie, Bendahl, Pär-Ola, Gallo, Widet, de Oliveira, Kelin Gonçalves, Ek, Lars, Bergman, Bengt, Sundberg, Jan, Melander, Olle, Belting, Mattias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909619/ https://www.ncbi.nlm.nih.gov/pubmed/35267617 http://dx.doi.org/10.3390/cancers14051307 |
Ejemplares similares
-
Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN—A Randomized Trial with Low Molecular Weight Heparin
por: Bendahl, Pär-Ola, et al.
Publicado: (2023) -
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial
por: Ek, L, et al.
Publicado: (2018) -
Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin
por: Gezelius, E., et al.
Publicado: (2018) -
Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer
por: Hagman, Helga, et al.
Publicado: (2018) -
Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status
por: Lidfeldt, Jon, et al.
Publicado: (2015)